A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumour.
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Dasatinib (Primary) ; Erlotinib (Primary) ; Lapatinib (Primary) ; Lenalidomide (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary) ; Valproic acid (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Dec 2011 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.